poisar

Stocks · News reference

Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate

Aug 6, 2026, 11:41 AMBenzinga Newsdesk

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses of $(0.28) per share

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

FHTX
Source
benzinga
Observed
Aug 6, 2026, 11:41 AM
Checked
Aug 6, 2026, 11:41 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Jul 1, 2026, 11:00 AMStep Pharma

    Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

    Step Pharma appoints Neil J. Gallagher, MD, PhD as Non-Executive Director to strengthen its board as it advances dencatistat, a first-in-class CTPS1 inhibitor, across three clinical programmes for essential thrombocythaemia, lymphoma, and solid tumours. Gallagher brings over 25 years of clinical development experience from senior roles at major pharmaceutical companies including Amgen, AstraZeneca, Novartis, and AbbVie.

    Read original at globenewswire-inc
    FHTX